Cilostazol inhibits platelet-monocytic THP1 cell aggregation, platelet CD4OL, and P-selectin expression

Go Shine Huang, Mei H. Hu, Tso Chou Lin, Chien Sung Tsai, Chian H. Lee, Wen Jinn Liaw

Research output: Contribution to journalArticle

Abstract

Background: Platelet activation is critical during inflammation, thrombosis, and tumor progression and metastasis. This activation leads to platelet-monocyte aggregation, platelet P-selectin, and CD40 ligand (CD40L) expression. Platelets can increase acute myelogenous leukemia (AML) blast proliferation. Cilostazol is widely used for arteriosclerosis obliterans and is known to inhibit platelet function. We hypothesized that cilostazol preconditioning impairs subsequent AML blast proliferation through a reduction in platelet activation. We aim to determine the effects of cilostazol on platelet activation as measured by platelet-monocyte aggregation, platelet P-selectin, and CD40L expression. Methods: Platelet-rich plasma samples from healthy volunteers were treated with cilostazol. THP1 is a human AML cell line that resembles human monocytes, which was used as a model to measure platelet-monocyte aggregation. The blood samples were stimulated by adenosine diphosphate (8 μ M) for evaluation of platelet-monocytic THP1 cell aggregation and P-selectin expression and were stimulated by thrombin (0. 1 U/mL) for detecting CD40L expression. All samples were stained with fluorochrome-conjugated antibodies and were analyzed by flow cytometry. Results: Pretreatment with cilostazol significantly suppressed platelet-monocytic THP1 cell aggregation, P-selectin, and CD40L expression in a concentration-dependent manner at concentrations of 101, 102, and 103 mM, respectively. Conclusions: Our data showed that cilostazol can downregulate not only cellular interactions between platelets and monocytic THP1 cells but also platelet P-selectin and CD40L expression.

Original languageEnglish
Pages (from-to)25-31
Number of pages7
JournalJournal of Medical Sciences (Taiwan)
Volume29
Issue number1
Publication statusPublished - Feb 2009

Fingerprint

Cell Aggregation
P-Selectin
Blood Platelets
CD40 Ligand
Monocytes
Platelet Activation
Platelet Aggregation
Acute Myeloid Leukemia
Arteriosclerosis Obliterans
Platelet-Rich Plasma
cilostazol
Fluorescent Dyes
Thrombin
Adenosine Diphosphate
Healthy Volunteers
Flow Cytometry
Thrombosis
Down-Regulation
Neoplasm Metastasis
Inflammation

Keywords

  • CD40L
  • Cilostazol
  • P-selectin
  • Platelet
  • THP1 cell

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cilostazol inhibits platelet-monocytic THP1 cell aggregation, platelet CD4OL, and P-selectin expression. / Huang, Go Shine; Hu, Mei H.; Lin, Tso Chou; Tsai, Chien Sung; Lee, Chian H.; Liaw, Wen Jinn.

In: Journal of Medical Sciences (Taiwan), Vol. 29, No. 1, 02.2009, p. 25-31.

Research output: Contribution to journalArticle

Huang, Go Shine ; Hu, Mei H. ; Lin, Tso Chou ; Tsai, Chien Sung ; Lee, Chian H. ; Liaw, Wen Jinn. / Cilostazol inhibits platelet-monocytic THP1 cell aggregation, platelet CD4OL, and P-selectin expression. In: Journal of Medical Sciences (Taiwan). 2009 ; Vol. 29, No. 1. pp. 25-31.
@article{caaee0d63edd40288da4bb83385d2da6,
title = "Cilostazol inhibits platelet-monocytic THP1 cell aggregation, platelet CD4OL, and P-selectin expression",
abstract = "Background: Platelet activation is critical during inflammation, thrombosis, and tumor progression and metastasis. This activation leads to platelet-monocyte aggregation, platelet P-selectin, and CD40 ligand (CD40L) expression. Platelets can increase acute myelogenous leukemia (AML) blast proliferation. Cilostazol is widely used for arteriosclerosis obliterans and is known to inhibit platelet function. We hypothesized that cilostazol preconditioning impairs subsequent AML blast proliferation through a reduction in platelet activation. We aim to determine the effects of cilostazol on platelet activation as measured by platelet-monocyte aggregation, platelet P-selectin, and CD40L expression. Methods: Platelet-rich plasma samples from healthy volunteers were treated with cilostazol. THP1 is a human AML cell line that resembles human monocytes, which was used as a model to measure platelet-monocyte aggregation. The blood samples were stimulated by adenosine diphosphate (8 μ M) for evaluation of platelet-monocytic THP1 cell aggregation and P-selectin expression and were stimulated by thrombin (0. 1 U/mL) for detecting CD40L expression. All samples were stained with fluorochrome-conjugated antibodies and were analyzed by flow cytometry. Results: Pretreatment with cilostazol significantly suppressed platelet-monocytic THP1 cell aggregation, P-selectin, and CD40L expression in a concentration-dependent manner at concentrations of 101, 102, and 103 mM, respectively. Conclusions: Our data showed that cilostazol can downregulate not only cellular interactions between platelets and monocytic THP1 cells but also platelet P-selectin and CD40L expression.",
keywords = "CD40L, Cilostazol, P-selectin, Platelet, THP1 cell",
author = "Huang, {Go Shine} and Hu, {Mei H.} and Lin, {Tso Chou} and Tsai, {Chien Sung} and Lee, {Chian H.} and Liaw, {Wen Jinn}",
year = "2009",
month = "2",
language = "English",
volume = "29",
pages = "25--31",
journal = "Journal of Medical Sciences",
issn = "1011-4564",
publisher = "國防醫學院",
number = "1",

}

TY - JOUR

T1 - Cilostazol inhibits platelet-monocytic THP1 cell aggregation, platelet CD4OL, and P-selectin expression

AU - Huang, Go Shine

AU - Hu, Mei H.

AU - Lin, Tso Chou

AU - Tsai, Chien Sung

AU - Lee, Chian H.

AU - Liaw, Wen Jinn

PY - 2009/2

Y1 - 2009/2

N2 - Background: Platelet activation is critical during inflammation, thrombosis, and tumor progression and metastasis. This activation leads to platelet-monocyte aggregation, platelet P-selectin, and CD40 ligand (CD40L) expression. Platelets can increase acute myelogenous leukemia (AML) blast proliferation. Cilostazol is widely used for arteriosclerosis obliterans and is known to inhibit platelet function. We hypothesized that cilostazol preconditioning impairs subsequent AML blast proliferation through a reduction in platelet activation. We aim to determine the effects of cilostazol on platelet activation as measured by platelet-monocyte aggregation, platelet P-selectin, and CD40L expression. Methods: Platelet-rich plasma samples from healthy volunteers were treated with cilostazol. THP1 is a human AML cell line that resembles human monocytes, which was used as a model to measure platelet-monocyte aggregation. The blood samples were stimulated by adenosine diphosphate (8 μ M) for evaluation of platelet-monocytic THP1 cell aggregation and P-selectin expression and were stimulated by thrombin (0. 1 U/mL) for detecting CD40L expression. All samples were stained with fluorochrome-conjugated antibodies and were analyzed by flow cytometry. Results: Pretreatment with cilostazol significantly suppressed platelet-monocytic THP1 cell aggregation, P-selectin, and CD40L expression in a concentration-dependent manner at concentrations of 101, 102, and 103 mM, respectively. Conclusions: Our data showed that cilostazol can downregulate not only cellular interactions between platelets and monocytic THP1 cells but also platelet P-selectin and CD40L expression.

AB - Background: Platelet activation is critical during inflammation, thrombosis, and tumor progression and metastasis. This activation leads to platelet-monocyte aggregation, platelet P-selectin, and CD40 ligand (CD40L) expression. Platelets can increase acute myelogenous leukemia (AML) blast proliferation. Cilostazol is widely used for arteriosclerosis obliterans and is known to inhibit platelet function. We hypothesized that cilostazol preconditioning impairs subsequent AML blast proliferation through a reduction in platelet activation. We aim to determine the effects of cilostazol on platelet activation as measured by platelet-monocyte aggregation, platelet P-selectin, and CD40L expression. Methods: Platelet-rich plasma samples from healthy volunteers were treated with cilostazol. THP1 is a human AML cell line that resembles human monocytes, which was used as a model to measure platelet-monocyte aggregation. The blood samples were stimulated by adenosine diphosphate (8 μ M) for evaluation of platelet-monocytic THP1 cell aggregation and P-selectin expression and were stimulated by thrombin (0. 1 U/mL) for detecting CD40L expression. All samples were stained with fluorochrome-conjugated antibodies and were analyzed by flow cytometry. Results: Pretreatment with cilostazol significantly suppressed platelet-monocytic THP1 cell aggregation, P-selectin, and CD40L expression in a concentration-dependent manner at concentrations of 101, 102, and 103 mM, respectively. Conclusions: Our data showed that cilostazol can downregulate not only cellular interactions between platelets and monocytic THP1 cells but also platelet P-selectin and CD40L expression.

KW - CD40L

KW - Cilostazol

KW - P-selectin

KW - Platelet

KW - THP1 cell

UR - http://www.scopus.com/inward/record.url?scp=61849171765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849171765&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:61849171765

VL - 29

SP - 25

EP - 31

JO - Journal of Medical Sciences

JF - Journal of Medical Sciences

SN - 1011-4564

IS - 1

ER -